Date: November 10, 2025

To,
The Manager - Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, Block-G,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051

SYMBOL: REMUS

Dear Sir/Madam,

Sub: Outcome of Board Meeting of the Company – Disclosure under Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

In compliance with Regulations 30 and 33 read with para-A of Part A of Schedule III and other applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors ("the Board") of the Company at their Meeting held today i.e., Monday, November 10, 2025 has inter-alia, approved the following:

1. **Half -yearly Financial Results**

   Unaudited Standalone and Consolidated Financial Results of the Company for the half year ended September 30, 2025, pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, together with the Limited Review Report thereon, issued by M/s. Pankaj R. Shah and Associates, Chartered Accountants.

   The financial results along with the report of the auditors of the Company are enclosed herewith as **Annexure-A**.

   Media Release in relation to the Unaudited Standalone and Consolidated financial results of the Company for the half year ended September 30, 2025 is enclosed as **Annexure -B.**

2. **Interim Dividend**

   The Board has approved 01st Interim Dividend of Rs. 0.50 (Fifty paise only) per equity share of face value of Rs. 10/- (Rupees Ten only) each fully paid up for the Financial Year 2025-26. The record date for the purpose of payment of Interim Dividend, as intimated earlier will be November 14, 2025.

3. **Approval of Notice of Postal Ballot**

   The Board has approved the Notice of Postal Ballot, calendar of events for Postal Ballot and has decided Friday, November 07, 2025 as the cut-off date for reckoning Voting Rights and ascertaining those Members to whom the Notice shall be sent through electronic means. The necessary details of the Postal Ballot including the Notice of Postal Ballot and e-Voting shall be intimated separately in due course.

Kindly note that the meeting of the Board of Directors of the Company commenced at 12:00 Noon (IST) and concluded at 02:25 P.M. (IST).

You are requested to take the aforesaid information on your record.

Thanking you
For, Remus Pharmaceuticals Limited

DEVAL BAKULKUMAR PATEL
Digitally signed by DEVAL BAKULKUMAR PATEL
Date: 2025.11.10 14:43:50 +05'30'

Deval Patel
Company Secretary and Compliance Officer
ICSI Membership No.: A60090

Enclosures: As above

Remus Pharmaceuticals Limited
REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.
P: 079 2999 9857
E. remus@remuspharma.com | W. www.remuspharma.com
GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536

Pankaj R Shah & Associates
Chartered Accountants

CA. DR. Pankaj Shah B.Com., F.C.A., Ph. D. (Commerce) | CA. Chintan Shah B.Com., L.L.B., F.C.A. | CA. Nilesh Shah B.Com., L.L.B., F.C.A. | CA. Manali Shah B.Com., F.C.A. | CA. Sandip Gupta B.Com., F.C.A.

7th Floor, Regency Plaza, Opp. Rahul Tower, Nr. Madhur Hall, Anandnagar Cross Road, Satellite, Ahmedabad-380015. India. Phone : +91 79 - 4603 1545, 4603 1546, 4032 1025. **URL : http://www.prsca.in**

Independent Auditors Review Report on Unaudited standalone financial results of Remus Pharmaceuticals Limited for the half year ended September 30, 2025 pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to,

The Board of Directors,

REMUS PHARMACEUTICALS LIMITED

Ahmedabad.

We have reviewed the accompanying statement of unaudited standalone financial results of **REMUS PHARMACEUTICALS LIMITED** (the "company") for the Half year ended September 30, 2025 (The "statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation, 2015, (the Regulation) as amended, (the "Listing Regulations").

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act, 2013, as amended read with relevant rules issued there under and other accounting principles generally accepted in India, read with the circular is the responsibility of the Company's Management and approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

ASSOCIATES ★ AHMEDABAD ★ CHARTERED ACCOUNTANTS

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (" Ind AS") as specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 10-11-2025
Place: Ahmedabad

For, Pankaj R Shah & Associates
Chartered Accountants
Registration No.107361W

N. R. Shah

CA Nilesh Shah
Partner
Membership No.107414
UDIN: 25107414BMGJZN1705

PANKAJ R. SHAH & ASSOCIATES
CHARTERED ACCOUNTANTS
AHMEDABAD

REMUS PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24232GJ2015PLC084536 | Website: www.remuspharma.com | Phone: +91-79-29999857 | E-mail: cs@remuspharma.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE PERIOD ENDED ON SEPTEMBER 30, 2025

(Rs. in Crore except for EPS)

Sr No.	Particulars	Half Year Ended on			Year Ended
		30th September, 2025 (Unaudited)	31st March , 2025 (Audited)	30th September, 2024 (Unaudited Restated)	31st March , 2025 (Audited)
I	Revenue from operations	46.85	41.49	37.67	79.16
II	Other income	2.80	0.96	1.95	2.91
III	**Total Income (I+II)**	**49.65**	**42.45**	**39.62**	**82.07**
IV	**Expenses**				
	Cost of materials consumed				
	Purchases of stock-in-trade	19.75	17.38	17.89	35.27
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.68	(0.07)	(0.16)	(0.23)
	Employee benefits expenses	4.37	5.24	3.93	9.17
	Finance costs	0.21	0.20	0.18	0.38
	Depreciation & Amortisation expenses	1.29	1.16	0.71	1.87
	Other expenses	7.28	4.20	4.77	8.97
	Total Expenses (IV)	**33.58**	**28.11**	**27.32**	**55.43**
V	**Profit before extraordinary items and tax (III-IV)**	**16.07**	**14.34**	**12.30**	**26.64**
VI	Extraordinary item		-	-	-
VII	**Profit before tax (V-VI)**	**16.07**	**14.34**	**12.30**	**26.64**
VIII	**Tax expense:**				
	Current tax	4.36	3.59	3.08	6.67
	Deferred tax	(0.32)	0.04	0.03	0.07
IX	**Profit for the period (VII-VIII)**	**12.03**	**10.71**	**9.19**	**19.90**
X	**Other Comprehensive Income**				
	A (i) Items that will not be reclassified subsequently to profit or loss	38.32	81.74	-	81.74
	(ii) Income tax relating to items that will not be reclassified subsequently to profit and loss	(5.48)	(11.69)	-	(11.69)
	B (i) Items that will be reclassified subsequently to profit or loss	(0.03)	(0.07)	-	(0.07)
	(ii) Income tax relating to items that will be reclassified subsequently to profit and loss	0.01	0.02	-	0.02
	Total Other Comprehensive Income for the period	32.82	70.00	-	70.00
XI	**Total Comprehensive Income for the period (IX+X)**	**44.85**	**80.71**	**9.19**	**89.90**
XII	**Paid up Share capital** *(face value Rs 10 per share)*	11.78	5.89	5.89	5.89
XIII	**Other Equity**				236.33
XIV	**Earnings per share**				
	Basic & Diluted *(Refer Note 8)*	10.21	9.09	7.80	16.88
	(EPS not annualized for the half yearly ended period)				

Place: Ahmedabad
Date: November 10, 2025

REMUS PHARMACEUTICALS LIMITED AHMEDABAD

For Remus Pharmaceuticals Limited,

Arpit Shah
Managing Director
DIN:07214641

Remus Pharmaceuticals Limited
Registered office: 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad Gujarat, India 380054
CIN: L24232GJ2015PLC084536 |Website: www.remuspharma.com | Phone: +91-79-29999857| E-mail: cs@remuspharma.com

Notes to Standalone Financial Results:

1. The above standalone unaudited financial results for the half year ended 30th September, 2025 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of Remus Pharmaceuticals Limited ("the Company") in their meeting held on 10th November, 2025.

2. The above standalone unaudited financial results for the half year ended on 30th September, 2025 are prepared in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies Accounting) Rules, 2014 as amended and other recognized accounting practices and policies, as applicable.

3. In accordance with Regulation 33 of the SEBI (LODR) Regulations 2015, the said standalone unaudited results have been reviewed by the Statutory Auditors of the Company for the half year ended on 30th September, 2025.

4. The Company had adopted Ind AS (Indian Accounting Standards) wef from April 1st, 2024. Hence, the figures for the corresponding half year ended on September 30th, 2024 which were earlier published under IGAAP (Indian Generally Accepted Accounting Principles) have been considered based on the restated unaudited figures.

5. The Statement also includes the standalone audited financial results for the half year ended on 31st March, 2025 being the balancing figure between the standalone audited figures in respect of the full financial year ended 31st March, 2025 and the published unaudited year-to-date figures up to the half year of the previous financial year.

6. The Company issued bonus shares in the ratio of 1:1 i.e. 1 (one) new fully paid-up Equity Shares of Rs.10/- (Rupees Ten only) each for every 1 (One) existing fully paid-up Equity Share of Rs. 10/- (Rupees Ten only) each held by the shareholders as on the 'Record Date' i.e. 04th July, 2025.

7. The Company operates in a single segment i.e. pharmaceutical product. Hence, the above financial results are based on single segment only.

8. EPS for the respective periods have been calculated based on the weighted average number of shares outstanding for the said periods. EPS has been adjusted to include the of impact of Bonus issue of shares for the corresponding previous periods.

9. The Board of Directors of the company in their meeting dated 10th November, 2025 have declared and approved the 1st Interim dividend of Rs 0.50 per share for the FY 2025-26.

10. The figures of the previous period have been re-grouped or rearranged, wherever considered necessary.

For, Remus Pharmaceuticals Limited,

Arpit Shah
Managing Director
DIN: 07214641

REMUS PHARMACEUTICALS LIMITED AHMEDABAD

Date: November 10, 2025
Place: Ahmedabad

REMUS PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24232GJ2015PLC084536 | Website: www.remuspharma.com | Phone: +91-79-29999857 | E-mail: cs@remuspharma.com

STATEMENT OF STANDALONE UNAUDITED BALANCE SHEET FOR THE PERIOD ENDED ON SEPTEMBER 30, 2025

(Rs. In Crore)

	Particulars	As at 30th September, 2025 (Unaudited)	As at 31st March, 2025 (Audited)
A	**ASSETS**		
1	**Non-current assets**		
(a)	Property, Plant and Equipment	7.01	4.89
(b)	Capital work-in-progress	-	-
(c)	Other Intangible assets	0.01	0.02
(d)	Intangible asset under development	0.06	0.06
(e)	Right to Use Assets	1.78	2.10
(f)	Financial Assets		
	Investments	247.19	208.80
	Loans	2.71	1.20
	Other Financial Assets	12.68	9.32
(g)	Deferred Tax Assets (net)	-	-
(h)	Other Non-Current Assets	-	0.01
		271.44	**226.40**
2	**Current assets**		
(a)	Inventories	1.44	2.12
(b)	Financial Assets		
	Investments	13.10	-
	Trade receivables	26.65	15.63
	Cash and cash equivalents	1.34	3.46
	Bank Balance other than above	1.17	0.91
	Loans	6.73	6.46
	Other Financial Assets	11.20	19.20
(c)	Current Tax Assets (Net)	-	-
(d)	Other current assets	4.55	6.13
		66.18	**53.91**
	TOTAL ASSETS	**337.62**	**280.31**
B	**EQUITY AND LIABILITIES**		
1	**Equity**		
(a)	Share capital	11.78	5.89
(b)	Other Equity	275.32	236.33
		287.10	**242.22**
	Liabilites		
	Non-current liabilities		
(a)	Financial Liabilities		
	Borrowings	3.80	1.78
	Lease Liabilities	1.13	1.66
(b)	Provisions	0.73	0.67
(c)	Deferred tax liabilities (net)	28.05	22.90
(d)	Other Non-Current Liabilities	-	-
		33.71	**27.01**
2	**Current liabilities**		
(a)	Financial Liabilities		
	Borrowings	0.28	0.36
	Lease Liabilities	0.76	0.51
	Trade payables		
	(A) Total Outstanding dues of Micro Enterprises and Small Enterprises	4.99	1.83
	(B) Total Outstanding dues of creditors other than Micro Enterprises and small Enterprise	3.66	3.22
	Other Financial Liabilities	0.31	0.25
(b)	Other current liabilities	4.50	4.61
(c)	Provisions	0.56	0.30
(d)	Current Tax Liabilities (Net)	1.75	-
		16.81	**11.08**
	TOTAL EQUITY AND LIABILITIES	**337.62**	**280.31**

For Remus Pharmaceuticals Limited,

Ashah

REMUS PHARMACEUTICALS LIMITED AHMEDABAD

Arpit Shah
Managing Director
DIN:07214641

Place: Ahmedabad
Date: November 10, 2025

REMUS PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24232GJ2015PLC084536 | Website: www.remuspharma.com | Phone: +91-79-29999857 | E-mail: cs@remuspharma.com

STATEMENT OF STANDALONE UNAUDITED CASH FLOW FOR THE PERIOD ENDED ON SEPTEMBER 30, 2025

(Rs. In Crore)

	Particulars	Half Year Ended 30th September, 2025 (Unaudited)	Half Year Ended 30th September, 2024 (Unaudited Restated)
(A)	**Cash Flow from Operating Activities :**		
	Net Profit before Tax	**16.07**	**12.31**
	Adjustments for :		
	Depreciation	1.29	0.71
	Interest Income	(1.23)	(0.86)
	Interest expenses	0.21	0.18
	(Profit) / Loss on sale of Property,Plant & Equipment	-	(0.21)
	Fair value gain on Investments through profit or loss statement	(0.09)	-
	Realised Gain on sale of Investments	(0.01)	-
	Operating cash flow Before Working Capital Changes	**16.24**	**12.12**
	Adjustments for:		
	Decrease/(Increase) in Other Current Assets	1.56	(3.55)
	Decrease/(Increase) in Other Non-Current Assets	0.01	-
	Decrease/(Increase) in Trade Receivables	(11.02)	(2.03)
	Decrease/(Increase) in Inventories	0.68	0.07
	Increase/(Decrease) in Other Current & Non-Current Liabilities	(0.11)	(0.45)
	Increase/(Decrease) in Trade Payables	3.60	1.86
	Increase/(Decrease) in Other Financial Liabilities	0.06	(0.17)
	Increase/(Decrease) in Provisions & tax liabilities	0.32	1.60
	Cash Generated from/(used in) Operating Activities	**11.34**	**9.45**
	Direct Taxes Paid (Net)	(2.62)	(3.23)
	Nat Cash from Operating Activities (A)	**8.71**	**6.22**
(B)	**Cash Flow from Investing Activity :**		
	Purchase of property, plant and equipment, Capital Work in Progress, leasehold asset and other intangible assets	(3.06)	(2.71)
	Decrease/(Increase) in Loans	(1.78)	(1.11)
	Decrease/(Increase) in Fixed Deposits	4.40	(2.00)
	Proceeds from Sale of Property, Plant & Equipment	-	0.30
	Sale / (Purchase) of Investments	(13.07)	(0.08)
	Interest Received	1.23	0.86
	Net Cash form Investing Activities (B)	**(12.28)**	**(4.73)**
(C)	**Cash Flow from Financing Activities :**		
	Proceeds from Issue of Equity Share Capital (payment toward issue expenses)	-	(0.04)
	Proceeds /(Repayment) of Long Term Borrowings (Net)	2.02	0.54
	Dividend Paid	-	(0.59)
	Proceeds /(Repayment) from Short Term Borrowings (Net)	(0.08)	0.31
	Increase/(Decrease) in Lease Liabilities	(0.28)	(0.24)
	Interest Paid	(0.21)	(0.18)
	Net Cash Flow from/(used in) Financing Activities (C)	**1.45**	**(0.19)**
	Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	**(2.12)**	**1.29**
	Add : Opening Cash & Cash Equivalents	3.46	1.71
	Closing Cash & Cash Equivalents	**1.34**	**3.00**

For Remus Pharmaceuticals Limited,

Arpit Shah
Managing Director
DIN:07214641

Place: Ahmedabad
Date: November 10, 2025

REMUS PHARMACEUTICALS LIMITED AHMEDABAD

Pankaj R Shah & Associates
Chartered Accountants

CA. DR. Pankaj Shah B.Com., F.C.A., Ph. D. (Commerce) | CA. Chintan Shah B.Com., L.L.B., F.C.A. | CA. Nilesh Shah B.Com., L.L.B., F.C.A. | CA. Manali Shah B.Com., F.C.A. | CA. Sandip Gupta B.Com., F.C.A.

7th Floor, Regency Plaza, Opp. Rahul Tower, Nr. Madhur Hall, Anandnagar Cross Road, Satellite, Ahmedabad-380015. India. Phone : +91 79 - 4603 1545, 4603 1546, 4032 1025. **URL : http://www.prsca.in**

Independent Auditors Review Report on Unaudited Consolidated Financial Results of Remus Pharmaceuticals Limited for the Half year ended September 30, 2025 pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,as amended

Review Report to,

The Board of Directors

REMUS PHARMACEUTICALS LTD
Ahmedabad.

We have reviewed the accompanying statement of unaudited consolidated financial results of **REMUS PHARMACEUTICALS LIMITED** (the "company") and its Subsidiaries (to gether the group) for the Half year ended September 30,2025. (the "statement") attached herewith, being submitted by the parent pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation, 2015, as amended (the listing Regulation) .

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act, 2013, as amended read with relevant rules issued there under and other accounting principles generally accepted in India, read with the circular is the responsibility of the Company's Management and approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing obligations & Disclosure Requirements) Regulation,2015, (the Regulation) as amended, to the extent applicable.
The statement includes the results of the following entities

Parent Company/Holding Company :

i. REMUS PHARMACEUTICALS LIMITED

PANKAJ R. SHAH & ASSOCIATES CHARTERED ACCOUNTANTS AHMEDABAD

Subsidiaries :

i. RELIUS PHARMA SRL

ii. ESPEE GLOBAL HOLDINGS LLC
iii. RELIUS PHARMACEUTICALS LIMITADA
iv. ESPEE GLOBAL CLINICAL TRIAL SERVICES PRIVATE LIMITED
v. ESPEE BIOPHARAMA & FINE CHEM LLC (STEPDOWN SUBSIDIARY)

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (" Ind AS") as specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

The Consolidated Financial Statements includes unaudited financial statements and other unaudited financial information in respect of 4 subsidiaries and 1 Step Down Subsidiary, whose financial statement reflect total assets of Rs 251.59 crores as at September 30, 2025, total revenues of Rs 356.54 crores and net cash inflow of Rs 1.55 crores for the half year then ended on 30th September 2025. These unaudited financial statements and other unaudited financial information have been furnished to us as certified by the management. Our Opinion, in so far as it relates to amounts and disclosures included in respect of four subsidiaries and one Step Down Subsidiary, is based solely on the unaudited financial statements and other unaudited financial information given to us by the management.

Date: 10-11-2025
Place: Ahmedabad

For, Pankaj R Shah & Associates
Chartered Accountants
Registration No.107361W

N. R. shah

PANKAJ R. SHAH & ASSOCIATES CHARTERED ACCOUNTANTS AHMEDABAD

CA Nilesh Shah
Partner
Membership No.107414
UDIN: 25107414BMGJZO3516

REMUS PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24232GJ2015PLC084536 | Website: www.remuspharma.com | Phone: +91-79-29999857 | E-mail: cs@remuspharma.com

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE PERIOD ENDED ON SEPTEMBER 30, 2025

(Rs. in Crore except for EPS)

Sr No.	Particulars	Half Year Ended on			Year Ended
		30th September, 2025 (Unaudited)	31st March, 2025 (Audited)	30 September, 2024 (Unaudited Restated)	31st March, 2025 (Audited)
I	Revenue from operations	400.20	347.75	272.61	620.36
II	Other income	2.93	2.63	2.35	4.98
III	**Total Income (I+II)**	**403.13**	**350.38**	**274.96**	**625.34**
IV	**Expenses**				
	Cost of materials consumed				
	Purchases of stock-in-trade	401.97	314.69	226.62	541.31
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(52.43)	(13.29)	4.85	(8.44)
	Employee benefits expenses	6.22	7.22	5.89	13.11
	Finance costs	0.65	0.64	0.82	1.46
	Depreciation & Amortisation expenses	1.29	1.16	0.71	1.87
	Other expenses	17.53	14.61	14.08	28.69
	Total Expenses (IV)	**375.23**	**325.03**	**252.97**	**578.00**
V	**Profit before extraordinary items and tax (III-IV)**	**27.90**	**25.35**	**21.99**	**47.34**
VI	Extraordinary item	-	-	-	-
VII	**Profit before tax (V-VI)**	**27.90**	**25.35**	**21.99**	**47.34**
VIII	**Tax expense:**				
	Current tax	6.63	4.74	4.11	8.85
	Deferred tax	(0.32)	0.04	0.03	0.07
IX	**Profit for the period (VII-VIII)**	**21.59**	**20.57**	**17.85**	**38.42**
X	**Profit / (Loss) from discontinuing operations (before tax)**	-	-	-	-
XI	Tax expense of discontinuing operations	-	-	-	-
XII	**Profit/(loss) from Discontinued operations (X-XI)**	-	-	-	-
XIII	**Profit for the period (IX+XII)**	**21.59**	**20.57**	**17.85**	**38.42**
XIV	**Other Comprehensive Income**				
	A (i) Items that will not be reclassified subsequently to profit or loss	38.32	81.87	-	81.87
	(ii) Income tax relating to items that will not be reclassified subsequently to profit and loss	(5.48)	(11.69)	-	(11.69)
	B (i) Items that will be reclassified subsequently to profit or loss	0.98	(0.07)	-	(0.07)
	(ii) Income tax relating to items that will be reclassified subsequently to profit and loss	0.01	0.02	-	0.02
	Total Other Comprehensive Income for the period	33.83	70.13	-	70.13
XV	**Total Comprehensive Income for the period (XIII+XIV)**	**55.42**	**90.70**	**17.85**	**108.55**
	Profit for the year attributable to				
	Owners of the Holding Company	17.50	16.01	13.06	29.07
	Non-Controling Interests	4.09	4.56	4.79	9.35
	Other Comprehensive Income attributable to				
	Owners of the Holding Company	33.62	70.33	(0.01)	70.31
	Non-Controling Interests	0.21	(0.20)	0.01	(0.18)
	Total Comprehensive Income attributable to				
	Owners of the Holding Company	51.12	86.33	13.05	99.38
	Non-Controling Interests	4.30	4.36	4.80	9.17
XVI	**Paid up Share capital** *(face value Rs 10 per share)*	11.78	5.89	5.89	5.89
XVII	**Other Equity**				249.97
XVIII	**Earnings per share**				
	Basic & Diluted *(Refer Note 9)* *(EPS not annualized for the half yearly ended period)*	18.33	17.46	15.14	32.61

For Remus Pharmaceuticals Limited,

REMUS PHARMACEUTICALS LIMITED AHMEDABAD

Arpit Shah
Managing Director
DIN:07214641

Place: Ahmedabad
Date: November 10, 2025

Remus Pharmaceuticals Limited

Registered office: 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad Gujarat, India 380054

CIN: L24232GJ2015PLC084536 |Website: www.remuspharma.com | Phone: +91-79-29999857| E-mail: cs@remuspharma.com

Notes to Consolidated Financial Results:

1. The above consolidated unaudited financial results for the half year ended on 30th September, 2025 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of Remus Pharmaceuticals Limited ("the Company") in their meeting held on 10th November, 2025.

2. The above consolidated unaudited financial results for the half year ended on 30th September, 2025 are prepared in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies Accounting) Rules, 2014 as amended and other recognized accounting practices and policies, as applicable.

3. In accordance with Regulation 33 of the SEBI (LODR) Regulations 2015, the said consolidated results have been reviewed by the Statutory Auditors of the Company for the half year ended on 30th September, 2025.

4. The Company had adopted Ind AS (Indian Accounting Standards) wef from April 1st, 2024. Hence, the figures for the corresponding half year ended on September 30th, 2024 which were earlier published under IGAAP (Indian Generally Accepted Accounting Principles) have been considered based on the restated unaudited figures.

5. The Statement also includes the consolidated audited financial results for the half year ended 31st March, 2025 being the balancing figure between the consolidated audited figures in respect of the full financial year ended 31st March, 2025 and the published unaudited restated year-to-date figures up to the half year of the previous financial year.

6. Below mentioned subsidiaries have been consolidated in the said financial results for half year ended on 30th September, 2025:

   i. Relius Pharma SRL (Bolivia)
   ii. Relius Pharmaceuticals Limitada (Guatemala)
   iii. Espee Global Holdings LLC (USA)
   iv. Espee Biopharma & Fine Chem LLC (Stepdown Subsidiary) (USA)
   v. Espee Global Clinical Trial Services Private Limited (India)

7. The Company issued bonus shares in the ratio of 1:1 i.e. 1 (One) new fully paid-up Equity Shares of Rs.10/- (Rupees Ten only) each for every 1 (One) existing fully paid-up Equity Share of Rs. 10/- (Rupees Ten only) each held by the shareholders as on the 'Record Date' i.e. 04th July, 2025.

8. The Company operates in a single segment i.e. pharmaceutical product. Hence, the above financial results are based on single segment only.

9. EPS for the respective periods have been calculated based on the weighted average number of shares outstanding for the said periods. EPS has been adjusted to include the of impact of Bonus issue of shares for the corresponding previous periods.

10. The Board of Directors of the company in their meeting dated 10th November, 2025 have declared and approved the 1st Interim dividend of Rs 0.50 per share for the FY 2025-26.

11. The figures of the previous period have been re-grouped or rearranged, wherever considered necessary.

For, Remus Pharmaceuticals Limited,

Arpit Shah
Managing Director
DIN: 07214641

REMUS PHARMACEUTICALS LIMITED AHMEDABAD

Date: November 10, 2025
Place: Ahmedabad

REMUS PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24232GJ2015PLC084536 | Website: www.remuspharma.com | Phone: +91-79-29999857 | E-mail: cs@remuspharma.com

STATEMENT OF CONSOLIDATED UNAUDITED BALANCE SHEET FOR THE PERIOD ENDED ON SEPTEMBER 30, 2025

(Rs. in Crore)

	Particulars	As at 30th September, 2025 (Unaudited)	As at 31st March, 2025 (Audited)
A	**ASSETS**		
1	**Non-current assets**		
(a)	Property, Plant and Equipment	7.04	4.91
(b)	Capital work-in-progress	0.23	-
(c)	Goodwill	8.73	8.73
(c)	Other Intangible assets	0.01	0.02
(d)	Intangible asset under development	0.06	0.06
(e)	Right to Use Assets	1.78	2.10
(f)	Financial Assets		
	Investments	224.48	186.12
	Loans	-	-
	Other Financial Assets	12.76	9.32
(g)	Deferred Tax Assets (net)	-	-
(h)	Other Non-Current Assets	-	0.01
		255.09	**211.27**
2	**Current assets**		
(a)	Inventories	105.53	51.56
(b)	Financial Assets		
	Investments	13.10	-
	Trade receivables	147.66	108.03
	Cash and cash equivalents	6.67	7.23
	Bank Balance other than above	1.17	0.91
	Loans	12.86	20.93
	Other Financial Assets	11.20	19.20
(c)	Current Tax Assets (Net)	-	-
(d)	Other current assets	14.93	13.51
		313.12	**221.37**
	TOTAL ASSETS	**568.21**	**432.64**
B	**EQUITY AND LIABILITIES**		
1	**Equity**		
(a)	Share capital	11.78	5.89
(b)	Other Equity	295.21	249.97
		306.99	**255.86**
	Non-Controlling Interest	30.99	26.69
	Total Equity	**337.98**	**282.55**
2	**Liabilties**		
	Non-current liabilities		
(a)	Financial Liabilities		
	Borrowings	5.40	3.33
	Lease Liabilities non current	1.13	1.66
(b)	Provisions	0.73	0.67
(c)	Deferred tax liabilities (net)	28.05	22.90
(d)	Other Non-Current Liabilities	-	-
		35.31	**28.56**
	Current liabilities		
(a)	Financial Liabilities		
	Borrowings	8.72	17.48
	Lease Liabilities current	0.76	0.51
	Trade payables		
	(A) Total Outstanding dues of Micro Enterprises and Small Enterprises	5.16	1.83
	(B) Total Outstanding dues of creditors other than Micro Enterprises and small Enterprise	119.88	69.46
	Other Financial Liabilities	0.31	0.32
(b)	Other current liabilities	53.36	28.35
(c)	Provisions current	1.16	0.77
(d)	Current Tax Liabilities (Net)	5.57	2.81
		194.92	**121.53**
	TOTAL EQUITY AND LIABILITIES	**568.21**	**432.64**

For Remus Pharmaceuticals Limited,

REMUS PHARMACEUTICALS LIMITED AHMEDABAD

Arpit Shah
Managing Director
DIN:07214641

Place: Ahmedabad
Date: November 10, 2025

REMUS PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24232GJ2015PLC084536 | Website: www.remuspharma.com | Phone: +91-79-29999857 | E-mail: cs@remuspharma.com

STATEMENT OF CONSOLIDATED UNAUDITED CASH FLOW FOR THE PERIOD ENDED ON SEPTEMBER 30, 2025

(Rs. in Crore)

	Particulars	Half Year ended on	
		30th September, 2025 (Unaudited)	30th September, 2024 (Unaudited restated)
(A)	**Cash Flow from Operating Activities :**		
	Net Profit before Tax	27.90	21.99
	Adjustments for :		
	Depreciation	1.29	0.71
	Interest Income	(1.23)	(0.86)
	Dividend Income	-	(0.68)
	Finance cost	0.65	0.82
	(Profit) / Loss on sale of Propert,Plant & Equipment	-	(0.21)
	Fair value gain on Investments through Profit or Loss statement	(0.09)	-
	Realised gain on sale of Investments	(0.01)	(0.13)
	Profit on account of translating financial statements of Foreign Subsidiaries	1.01	0.32
	Operating Cash Flow Before Working Capital Changes	**29.52**	**21.96**
	Adjustments for:		
	Decrease/(Increase) in Other Current Assets	(1.52)	(7.29)
	Decrease/(Increase) in Other Non-Current Assets	0.01	-
	Decrease/(Increase) in Trade Receivables	(39.64)	55.61
	Decrease/(Increase) in Inventories	(53.97)	5.25
	Increase/(Decrease) in Other Current & Non-Current Liabilities	25.02	(6.14)
	Increase/(Decrease) in Trade Payables	53.75	(56.05)
	Increase/(Decrease) in Other Financial Liabilities	(0.01)	(0.17)
	Increase/(Decrease) in Provisions	0.45	0.42
	Cash Generated from/(used in) Operating Activities	**13.61**	**13.60**
	Direct Taxes Paid (Net)	(3.87)	(3.66)
	Nat Cash from Operating Activities (A)	**9.74**	**9.94**
(B)	**Cash Flow from Investing Activity :**		
	Purchase of property, plant and equipment, Capital Work in Progress, leasehold asset and other intangible assets	(3.31)	(2.75)
	Proceeds from Sale of Property, Plant & Equipment	-	0.30
	Decrease/(Increase) in Loans	8.07	(0.09)
	Decrease/(Increase) in Fixed Deposits	4.40	(2.00)
	Sale/(Purchase) of Investments in Financial instruments	(13.07)	2.63
	Dividend Received	-	0.68
	Interest Received	1.23	0.86
	Net Cash form Investing Activities (B)	**(2.68)**	**(0.37)**
(C)	**Cash Flow from Financing Activities :**		
	Proceeds from Issue of Equity Share Capital (Net of issue expenses)	-	(0.04)
	Proceeds /(Repayment) of Long Term Borrowings (Net)	2.07	0.54
	Dividend Paid	-	(0.59)
	Proceeds /(Repayment) from Short Term Borrowings (Net)	(8.76)	8.75
	Increase/(Decrease) in Lease Liabilities	(0.28)	(0.24)
	Finance cost	(0.65)	(0.82)
	Net Cash Flow from/(used in) Financing Activities (C)	**(7.62)**	**7.61**
	Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	**(0.56)**	**17.18**
	Add : Opening Cash & Cash Equivalents	7.23	4.72
	Closing Cash & Cash Equivalents	**6.67**	**21.90**

For Remus Pharmaceuticals Limited

Arpit Shah
Managing Director
DIN:07214641

Place: Ahmedabad
Date: November 10, 2025

Media Release

REMUS PHARMACEUTICALS LIMITED REPORTS H1-FY26 CONSOLIDATED PROFIT AFTER TAX OF INR 17.50 CRORES WITH A 33.97 % GROWTH COMPARED TO H1-FY25

November 10, 2025: Remus Pharmaceuticals Limited (NSE-SME: REMUS) announces its results for the half year ended September 30, 2025

Consolidated Financial Performance:

H1 FY26 vs H1 FY25

Revenue From Operations	EBITDA	PAT
H1 FY26: 400.20 INR Cr	**H1 FY26: 26.91 INR Cr**	**H1 FY26[1]: 17.50 INR Cr**
H1 FY25: 272.61 INR Cr	**H1 FY25: 21.18 INR Cr**	**H1 FY25: 13.06 INR Cr**
Growth: 46.80% ↑	*Growth: 27.08%* ↑	*Growth: 33.97%* ↑

H1-FY26 Business Highlights:

- **Successful Tender Achievement – Nicaragua**
  Remus participated in the **Nicaragua national tender** and **successfully secured two key product awards**, strengthening its presence in the Central American region.

- **Introduction of a New Therapeutic Segment**
  Launched **Rivastigmine Patch** across multiple markets, marking Remus's expansion into a **new therapeutic category**.

- **Strong Market Performance – Bolivia (Private Market)**
  Relius Pharma SRL (Bolivian subsidiary of Remus) achieved successful **commercial launches** of the following key products:
  • Rivaroxaban 10 mg Tablet
  • Eltrombopag 25 mg Tablet
  • Carbidopa + Levodopa 250 mg + 25 mg Tablet
  • Cefepime 1 gm Injection

- **Regulatory Milestone – Myanmar**
  Secured **37 new product approvals** between **April to September 2025**, further strengthening Remus's regulatory footprint in the ASEAN region.

- **New Market Expansion – Algeria**
  Successfully **entered the Algerian market** and **initiated product registration activities**, opening new growth opportunities in North Africa.

- **Tender Participation – Mauritania & Kuwait**
  Participated in **national tenders with 20 products in each country**; reflecting Remus's ongoing efforts to broaden tender market reach.

Management Comments:

Commenting on the results, Mr. Arpit Deepakkumar Shah, Managing Director of Remus Pharmaceuticals Limited said, "*The Company has maintained the growth trajectory for the first half of the financial year and*

[1] *PAT before Minority **Interest for** H1 FY26 is 21.59 INR crores*

has met our expectations. The growth that we have achieved testifies the hard work and dedication of our team. Going forward we are looking to expand our reach to new markets and product segments. Our government institutional tenders and rigorous penetration in B2C markets will glorify our trajectory of a better second half of current financial year. We are confident that our strong and strategic performance will continue to drive our growth in the future."

Financial Statements:

Results for the half year ended September 30, 2025, prepared under Ind AS, are available in the Investors section of our website https://remuspharma.com/

About Remus Pharmaceuticals Limited:

Remus Pharmaceuticals Limited is engaged in exporting, marketing and distribution of finished formulations of pharmaceutical drugs. Having strong footprints in 40+ countries across the globe, Remus is involved in the sales of niche, specialized and critical care finished formulations. Remus is actively engaged in D2C via Pharmacy networks for specialty niche formulations through its subsidiaries in various markets.

Safe Harbor

This document includes certain forward-looking statements which are tentative, based on current expectations of the management of Remus Pharmaceuticals Limited or any of its subsidiaries ("Remus"). These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological, and/or regulatory factors, exchange rate fluctuations, cash flow projections, interest, and other costs. Remus, its directors, and any of the affiliates or employees are under no obligation to and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise. Remus does not undertake any obligation to revise or update any forward-looking statement that may be made from time to time by or on behalf of the Company including to reflect actual results, changes in assumptions or changes in factors affecting these statements.

Follow Remus Pharmaceuticals Limited on LinkedIn: https://www.linkedin.com/company/remus-pharmaceuticals/

Contact Information:

Investor Relations Representative:	**Chief Financial Officer**
Mr. Anuj Sonpal Valorem Advisors Tel: +91-22-4903-9500 Email: remus@valoremadvisors.com	Ms. Anjali Shah Remus Pharmaceuticals Limited Email: ir@remuspharma.com